|
"chun jen liu"的相关文件
显示项目 471-480 / 543 (共55页)
<< < 43 44 45 46 47 48 49 50 51 52 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2018-09-10T07:37:25Z |
Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses
|
Liu, Chun-Jen;Chuang, Wan-Long;Lee, Chuan-Mo;Yu, Ming-Lung;Lu, Sheng-Nan;Wu, Shun-Sheng;Chen, Chi-Ling;Yang, Sien-Sing;Kao, Jia-Horng;Liu, Chen-Hua;Su, Wei-Wen;Jeng, Yung-Ming;Chen, Pei-Jer;Chen, Ding-Shinn; CHUN-JEN LIU; YUNG-MING JENG; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO; LIU, CHUN-JEN; CHUANG, WAN-LONG; LEE, CHUAN-MO; YU, MING-LUNG; LU, SHENG-NAN; WU, SHUN-SHENG; CHEN, CHI-LING; YANG, SIEN-SING; KAO, JIA-HORNG; LIU, CHEN-HUA; SU, WEI-WEN; JENG, YUNG-MING; CHEN, PEI-JER; CHEN, DING-SHINN |
| 臺大學術典藏 |
2018-09-10T07:35:35Z |
Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study
|
Shih, W.-L. and Yu, M.-W. and Chen, P.-J. and Wu, T.-W. and Lin, C.-L. and Liu, C.-J. and Lin, S.-M. and Tai, D.-I. and Lee, S.-D. and Liaw, Y.-F.; 施惟量;于明暉;陳培哲;吳泰瑋;林志陵;劉俊人;林錫銘;戴達英;李壽東;廖運範; SHIH, WEI-LIANG;YU, MING-WHEI;CHEN, PEI -JER;WU, TAI-WEI;LIN, CHIH-LIN;LIU, CHUN-JEN;LIN, SHI-MING;TAI, DAR-IN;LEE, SHOU-DONG;LIAW, YUN-FAN; MING-WHEI YU; CHUN-JEN LIU; PEI-JER CHEN; YU, MING-WHEI; WU, TAI-WEI; LIN, CHIH-LIN; LIU, CHUN-JEN; LIN, SHI-MING; TAI, DAR-IN; LEE, SHOU-DONG; LIAW, YUN-FAN |
| 臺大學術典藏 |
2018-09-10T07:35:35Z |
Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection
|
Hsu, C.-S.;Liu, C.-H.;Liu, C.-J.;Wang, C.-C.;Chen, C.-L.;Lai, M.-Y.;Chen, P.-J.;Chen, D.-S.;Kao, J.-H.; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T07:35:34Z |
Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B
|
Liu, Chun-Jen;Jeng, Yung-Ming;Chen, Chi-Ling;Chen, Pei-Jer;Chen, Ting-Chi;Liu, Chen-Hua;Lai, Ming-Yang;Chen, Ding-Shinn;Kao, Jia-Horng; CHUN-JEN LIU; PEI-JER CHEN; YUNG-MING JENG; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO; LIU, CHUN-JEN; JENG, YUNG-MING; CHEN, CHI-LING; CHEN, PEI-JER; CHEN, TING-CHI; LIU, CHEN-HUA; LAI, MING-YANG; CHEN, DING-SHINN; KAO, JIA-HORNG |
| 臺大學術典藏 |
2018-09-10T07:35:33Z |
Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus
|
PEI-JER CHEN; CHUNG-YI HU; DING-SHINN CHEN; JIA-HORNG KAO; HUANG, YI-WEN; HU, CHUNG-YI; CHEN, CHI-LING; LIAO, YA-TANG; LIU, CHUN-JEN; LAI, MING-YANG; CHEN, PEI-JER; YANG, SIEN-SING; HU, JUI-TING; CHEN, DING-SHINN; KAO, JIA-HORNG; CHUN-JEN LIU; Huang, Yi-Wen;Hu, Chung-Yi;Chen, Chi-Ling;Liao, Ya-Tang;Liu, Chun-Jen;Lai, Ming-Yang;Chen, Pei-Jer;Yang, Sien-Sing;Hu, Jui-Ting;Chen, Ding-Shinn;Kao, Jia-Horng; YI-WEN HUANG |
| 臺大學術典藏 |
2018-09-10T07:35:33Z |
High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection
|
Liu, Chun-Jen;Chen, Pei-Jer;Lai, Ming-Yang;Liu, Chen-Hua;Chen, Chi-Ling;Kao, Jia-Horng;Chen, Ding-Shinn; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO; LIU, CHUN-JEN; CHEN, PEI-JER; LAI, MING-YANG; LIU, CHEN-HUA; CHEN, CHI-LING; KAO, JIA-HORNG; CHEN, DING-SHINN |
| 臺大學術典藏 |
2018-09-10T07:35:33Z |
Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C
|
Hsieh, T.-H.;Tseng, T.-C.;Liu, C.-J.;Lai, M.-Y.;Chen, P.-J.;Hsieh, H.-L.;Chen, D.-S.;Kao, J.-H.; CHUN-JEN LIU; PEI-JER CHEN; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T07:35:31Z |
Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy
|
Liu, C.-H.;Liang, C.-C.;Liu, C.-J.;Tsai, H.-B.;Hung, P.-H.;Hsu, S.-J.;Chen, S.-L.;Lin, J.-W.;Lai, M.-Y.;Chen, J.-H.;Chen, P.-J.;Chen, D.-S.;Kao, J.-H.; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T07:26:51Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, C.-J. and Lee, P.-H. and Lin, D.-Y. and Wu, C.-C. and Jeng, L.-B. and Lin, P.-W. and Mok, K.-T. and Lee, W.-C. and Yeh, H.-Z. and Ho, M.-C. and Yang, S.-S. and Lee, C.-C. and Yu, M.-C. and Hu, R.-H. and Peng, C.-Y. and Lai, K.-L. and Chang, S.S.-C. and Chen, P.-J.; 劉俊人;李伯皇;胡瑞恆;吳誠中;鄭隆賓;林炳文;莫景棠;葉宏仁;何明志;楊勝舜;陳培哲; LIU, CHUN-JEN;LEE, PO-HUANG;HU, REY-HENG;WU, CHENG-CHUNG;JENG, LONG-BIN;LIN, PIN-WEN;MOK, KING-TONG;YEH, HONG-ZEN;HO, MING-CHIH;YANG, SHENG-SHUN;CHEN, PEI-JER; MING-CHIH HO; PO-HUANG LEE; CHUN-JEN LIU; PEI-JER CHEN; REY-HENG HU; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 臺大學術典藏 |
2018-09-10T07:11:03Z |
Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma
|
Chou, Y.-C.;Yu, M.-W.;Wu, C.-F.;Yang, S.-Y.;Lin, C.-L.;Liu, C.-J.;Shin, W.-L.;Chen, P.-J.;Liaw, Y.-F.;Chen, C.-J.; MING-WHEI YU; Chou, YC; CHUN-JEN LIU; Yu, MW; Wu, CF; Yang, SY; Lin, CL; Liu, CJ; Shih, WL; Chen, PJ; Liaw, YF; Chen, CJ. |
显示项目 471-480 / 543 (共55页)
<< < 43 44 45 46 47 48 49 50 51 52 > >>
每页显示[10|25|50]项目
|
